2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2674

Cis-Expression Quantitative Trait Loci Analysis of Dysregulated Interferon-Pathway Genes Identifies HLA-C and OAS1 As Novel Candidates for Susceptibility to Sjögren’s Syndrome
Abstract Number: 737

Citrullination of ENA-78/CXCL5 Results in Conversion From a Non-Monocyte Recruiting to a Monocyte Recruiting Chemokine
Abstract Number: 1690

Citrullination within the Atherosclerotic Plaque: A New Potential Target for Anti-Citrullinated Protein Antibodies
Abstract Number: 2202

Classification Criteria for Sjögren’s Syndrome: Comparison of the Performance of the 2002 American-European Consensus Group Criteria (AECG) and the 2012 ACR Criteria
Abstract Number: L3

Classification Criteria for Systemic Sclerosis: Preliminary Results
Abstract Number: 1734

Clinical Accuracy for Diagnosis of Antiphospholipid Syndrome in Systemic Lupus Erythematosus: Evaluation of 23 Possible Combinations of Antiphospholipid Antibody Specificities
Abstract Number: 797

Clinical and Biomechanical Characteristics of Total Hip Arthroplasty Responders and Nonresponders
Abstract Number: 282

Clinical and Laboratory Features Distinguishing Juvenile Polymyositis and Muscular Dystrophy in Children
Abstract Number: 192

Clinical and Laboratory Findings in A Cohort of Italian Patients with Adult Onset Still’S Disease: The Role of IL-18 As A Disease Biomarker
Abstract Number: 1594

Clinical and Radiological Outcomes After One Year of Remission Steered Combination Treatment in Patients with Early Rheumatoid and Undifferentiated Arthritis
Abstract Number: 1598

Clinical and Serologic Predictors of Response in Rituximab-Treated Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) – the RIM Study
Abstract Number: 216

Clinical and Serological Associations of Malignancy in Adult Patients with Polymyositis and Dermatomyositis
Abstract Number: 1166

Clinical and Therapeutic Features of 312 Patients with Macrophage Activation Syndrome Enrolled in a Multinational Survey
Abstract Number: 1370

Clinical and Ultrasonographic Features of Nail Disease in Psoriasis and Psoriatic Arthritis
Abstract Number: 1422

Clinical Associations of Anti-Smith Antibodies in Profile: A Multiethnic Lupus Cohort

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].